

Global Peptide and Oligonucleotide CDMO Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G508B1BB50E2EN.html>

Date: June 2024

Pages: 146

Price: US\$ 3,200.00 (Single User License)

ID: G508B1BB50E2EN

Abstracts

Report Overview:

The Global Peptide and Oligonucleotide CDMO Market Size was estimated at USD 1763.67 million in 2023 and is projected to reach USD 3124.45 million by 2029, exhibiting a CAGR of 10.00% during the forecast period.

This report provides a deep insight into the global Peptide and Oligonucleotide CDMO market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Peptide and Oligonucleotide CDMO Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Peptide and Oligonucleotide CDMO market in any manner.

Global Peptide and Oligonucleotide CDMO Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Lonza Group Ltd.

Thermo Fisher Scientific Inc.

Merck KGaA

Catalent, Inc.

Genscript Biotech Corporation

Polypeptide Group

Bachem Holding AG

Wuxi Apptec Co., Ltd.

Ajinomoto Co., Inc.

Rentschler Biopharma SE

Corden Pharma GmbH

Senn Chemicals AG

Almac Group

Lonza Custom Manufacturing

Creative Peptides

Swiss Customized Synthesis

Syngene

Eurogentec

Market Segmentation (by Type)

Peptide CDMO

Oligonucleotide CDMO

Market Segmentation (by Application)

Pharmaceutical and Biotechnology Companies

Research Institutes

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Peptide and Oligonucleotide CDMO Market

Overview of the regional outlook of the Peptide and Oligonucleotide CDMO Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each

region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future

development potential, and so on. It offers a high-level view of the current state of the Peptide and Oligonucleotide CDMO Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Peptide and Oligonucleotide CDMO

1.2 Key Market Segments

1.2.1 Peptide and Oligonucleotide CDMO Segment by Type

1.2.2 Peptide and Oligonucleotide CDMO Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Peptide and Oligonucleotide CDMO Market Size (M USD) Estimates and Forecasts (2019-2030)

2.1.2 Global Peptide and Oligonucleotide CDMO Sales Estimates and Forecasts (2019-2030)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET COMPETITIVE LANDSCAPE

3.1 Global Peptide and Oligonucleotide CDMO Sales by Manufacturers (2019-2024)

3.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Manufacturers (2019-2024)

3.3 Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Peptide and Oligonucleotide CDMO Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Peptide and Oligonucleotide CDMO Sales Sites, Area Served, Product Type

3.6 Peptide and Oligonucleotide CDMO Market Competitive Situation and Trends

3.6.1 Peptide and Oligonucleotide CDMO Market Concentration Rate

3.6.2 Global 5 and 10 Largest Peptide and Oligonucleotide CDMO Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 PEPTIDE AND OLIGONUCLEOTIDE CDMO INDUSTRY CHAIN ANALYSIS

4.1 Peptide and Oligonucleotide CDMO Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Peptide and Oligonucleotide CDMO Sales Market Share by Type (2019-2024)

6.3 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2019-2024)

6.4 Global Peptide and Oligonucleotide CDMO Price by Type (2019-2024)

7 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Peptide and Oligonucleotide CDMO Market Sales by Application

(2019-2024)

7.3 Global Peptide and Oligonucleotide CDMO Market Size (M USD) by Application

(2019-2024)

7.4 Global Peptide and Oligonucleotide CDMO Sales Growth Rate by Application

(2019-2024)

8 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SEGMENTATION BY REGION

8.1 Global Peptide and Oligonucleotide CDMO Sales by Region

8.1.1 Global Peptide and Oligonucleotide CDMO Sales by Region

8.1.2 Global Peptide and Oligonucleotide CDMO Sales Market Share by Region

8.2 North America

8.2.1 North America Peptide and Oligonucleotide CDMO Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Peptide and Oligonucleotide CDMO Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Peptide and Oligonucleotide CDMO Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Peptide and Oligonucleotide CDMO Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Peptide and Oligonucleotide CDMO Sales by Region

8.6.2 Saudi Arabia

- 8.6.3 UAE
- 8.6.4 Egypt
- 8.6.5 Nigeria
- 8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Lonza Group Ltd.

- 9.1.1 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Basic Information
- 9.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Overview
- 9.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Market Performance
- 9.1.4 Lonza Group Ltd. Business Overview
- 9.1.5 Lonza Group Ltd. Peptide and Oligonucleotide CDMO SWOT Analysis
- 9.1.6 Lonza Group Ltd. Recent Developments

9.2 Thermo Fisher Scientific Inc.

- 9.2.1 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Basic Information
- 9.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Overview
- 9.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Market Performance
- 9.2.4 Thermo Fisher Scientific Inc. Business Overview
- 9.2.5 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO SWOT Analysis
- 9.2.6 Thermo Fisher Scientific Inc. Recent Developments

9.3 Merck KGaA

- 9.3.1 Merck KGaA Peptide and Oligonucleotide CDMO Basic Information
- 9.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Overview
- 9.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Product Market Performance
- 9.3.4 Merck KGaA Peptide and Oligonucleotide CDMO SWOT Analysis
- 9.3.5 Merck KGaA Business Overview
- 9.3.6 Merck KGaA Recent Developments

9.4 Catalent, Inc.

- 9.4.1 Catalent, Inc. Peptide and Oligonucleotide CDMO Basic Information
- 9.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Overview
- 9.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Market Performance
- 9.4.4 Catalent, Inc. Business Overview
- 9.4.5 Catalent, Inc. Recent Developments

9.5 Genscript Biotech Corporation

9.5.1 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Basic Information

9.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Overview

9.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Market Performance

9.5.4 Genscript Biotech Corporation Business Overview

9.5.5 Genscript Biotech Corporation Recent Developments

9.6 Polypeptide Group

9.6.1 Polypeptide Group Peptide and Oligonucleotide CDMO Basic Information

9.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Overview

9.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Product Market Performance

9.6.4 Polypeptide Group Business Overview

9.6.5 Polypeptide Group Recent Developments

9.7 Bachem Holding AG

9.7.1 Bachem Holding AG Peptide and Oligonucleotide CDMO Basic Information

9.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Overview

9.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Market Performance

9.7.4 Bachem Holding AG Business Overview

9.7.5 Bachem Holding AG Recent Developments

9.8 Wuxi Apptec Co., Ltd.

9.8.1 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Basic Information

9.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Overview

9.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Market Performance

9.8.4 Wuxi Apptec Co., Ltd. Business Overview

9.8.5 Wuxi Apptec Co., Ltd. Recent Developments

9.9 Ajinomoto Co., Inc.

9.9.1 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Basic Information

9.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Overview

9.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Market Performance

9.9.4 Ajinomoto Co., Inc. Business Overview

9.9.5 Ajinomoto Co., Inc. Recent Developments

9.10 Rentschler Biopharma SE

9.10.1 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Basic

Information

9.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product

Overview

9.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Market Performance

9.10.4 Rentschler Biopharma SE Business Overview

9.10.5 Rentschler Biopharma SE Recent Developments

9.11 Corden Pharma GmbH

9.11.1 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Basic Information

9.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Overview

9.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Market Performance

9.11.4 Corden Pharma GmbH Business Overview

9.11.5 Corden Pharma GmbH Recent Developments

9.12 Senn Chemicals AG

9.12.1 Senn Chemicals AG Peptide and Oligonucleotide CDMO Basic Information

9.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Overview

9.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Market Performance

9.12.4 Senn Chemicals AG Business Overview

9.12.5 Senn Chemicals AG Recent Developments

9.13 Almac Group

9.13.1 Almac Group Peptide and Oligonucleotide CDMO Basic Information

9.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Overview

9.13.3 Almac Group Peptide and Oligonucleotide CDMO Product Market Performance

9.13.4 Almac Group Business Overview

9.13.5 Almac Group Recent Developments

9.14 Lonza Custom Manufacturing

9.14.1 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Basic Information

9.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Overview

9.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Market Performance

9.14.4 Lonza Custom Manufacturing Business Overview

9.14.5 Lonza Custom Manufacturing Recent Developments

9.15 Creative Peptides

9.15.1 Creative Peptides Peptide and Oligonucleotide CDMO Basic Information

9.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Overview

9.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Product Market Performance

9.15.4 Creative Peptides Business Overview

9.15.5 Creative Peptides Recent Developments

9.16 Swiss Customized Synthesis

9.16.1 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Basic Information

9.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Overview

9.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Market Performance

9.16.4 Swiss Customized Synthesis Business Overview

9.16.5 Swiss Customized Synthesis Recent Developments

9.17 Syngene

9.17.1 Syngene Peptide and Oligonucleotide CDMO Basic Information

9.17.2 Syngene Peptide and Oligonucleotide CDMO Product Overview

9.17.3 Syngene Peptide and Oligonucleotide CDMO Product Market Performance

9.17.4 Syngene Business Overview

9.17.5 Syngene Recent Developments

9.18 Eurogentec

9.18.1 Eurogentec Peptide and Oligonucleotide CDMO Basic Information

9.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Overview

9.18.3 Eurogentec Peptide and Oligonucleotide CDMO Product Market Performance

9.18.4 Eurogentec Business Overview

9.18.5 Eurogentec Recent Developments

10 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET FORECAST BY REGION

10.1 Global Peptide and Oligonucleotide CDMO Market Size Forecast

10.2 Global Peptide and Oligonucleotide CDMO Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Peptide and Oligonucleotide CDMO Market Size Forecast by Country

10.2.3 Asia Pacific Peptide and Oligonucleotide CDMO Market Size Forecast by Region

10.2.4 South America Peptide and Oligonucleotide CDMO Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Peptide and Oligonucleotide CDMO by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Peptide and Oligonucleotide CDMO Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Peptide and Oligonucleotide CDMO by Type (2025-2030)

11.1.2 Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Peptide and Oligonucleotide CDMO by Type (2025-2030)

11.2 Global Peptide and Oligonucleotide CDMO Market Forecast by Application (2025-2030)

11.2.1 Global Peptide and Oligonucleotide CDMO Sales (K Units) Forecast by Application

11.2.2 Global Peptide and Oligonucleotide CDMO Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Peptide and Oligonucleotide CDMO Market Size Comparison by Region (M USD)

Table 5. Global Peptide and Oligonucleotide CDMO Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Peptide and Oligonucleotide CDMO Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Peptide and Oligonucleotide CDMO Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Peptide and Oligonucleotide CDMO Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide and Oligonucleotide CDMO as of 2022)

Table 10. Global Market Peptide and Oligonucleotide CDMO Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Peptide and Oligonucleotide CDMO Sales Sites and Area Served

Table 12. Manufacturers Peptide and Oligonucleotide CDMO Product Type

Table 13. Global Peptide and Oligonucleotide CDMO Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Peptide and Oligonucleotide CDMO

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Peptide and Oligonucleotide CDMO Market Challenges

Table 22. Global Peptide and Oligonucleotide CDMO Sales by Type (K Units)

Table 23. Global Peptide and Oligonucleotide CDMO Market Size by Type (M USD)

Table 24. Global Peptide and Oligonucleotide CDMO Sales (K Units) by Type (2019-2024)

Table 25. Global Peptide and Oligonucleotide CDMO Sales Market Share by Type

(2019-2024)

Table 26. Global Peptide and Oligonucleotide CDMO Market Size (M USD) by Type (2019-2024)

Table 27. Global Peptide and Oligonucleotide CDMO Market Size Share by Type (2019-2024)

Table 28. Global Peptide and Oligonucleotide CDMO Price (USD/Unit) by Type (2019-2024)

Table 29. Global Peptide and Oligonucleotide CDMO Sales (K Units) by Application

Table 30. Global Peptide and Oligonucleotide CDMO Market Size by Application

Table 31. Global Peptide and Oligonucleotide CDMO Sales by Application (2019-2024) & (K Units)

Table 32. Global Peptide and Oligonucleotide CDMO Sales Market Share by Application (2019-2024)

Table 33. Global Peptide and Oligonucleotide CDMO Sales by Application (2019-2024) & (M USD)

Table 34. Global Peptide and Oligonucleotide CDMO Market Share by Application (2019-2024)

Table 35. Global Peptide and Oligonucleotide CDMO Sales Growth Rate by Application (2019-2024)

Table 36. Global Peptide and Oligonucleotide CDMO Sales by Region (2019-2024) & (K Units)

Table 37. Global Peptide and Oligonucleotide CDMO Sales Market Share by Region (2019-2024)

Table 38. North America Peptide and Oligonucleotide CDMO Sales by Country (2019-2024) & (K Units)

Table 39. Europe Peptide and Oligonucleotide CDMO Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Peptide and Oligonucleotide CDMO Sales by Region (2019-2024) & (K Units)

Table 41. South America Peptide and Oligonucleotide CDMO Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Peptide and Oligonucleotide CDMO Sales by Region (2019-2024) & (K Units)

Table 43. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Basic Information

Table 44. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Overview

Table 45. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 46. Lonza Group Ltd. Business Overview

Table 47. Lonza Group Ltd. Peptide and Oligonucleotide CDMO SWOT Analysis

Table 48. Lonza Group Ltd. Recent Developments

Table 49. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Basic Information

Table 50. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Overview

Table 51. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 52. Thermo Fisher Scientific Inc. Business Overview

Table 53. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO SWOT Analysis

Table 54. Thermo Fisher Scientific Inc. Recent Developments

Table 55. Merck KGaA Peptide and Oligonucleotide CDMO Basic Information

Table 56. Merck KGaA Peptide and Oligonucleotide CDMO Product Overview

Table 57. Merck KGaA Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 58. Merck KGaA Peptide and Oligonucleotide CDMO SWOT Analysis

Table 59. Merck KGaA Business Overview

Table 60. Merck KGaA Recent Developments

Table 61. Catalent, Inc. Peptide and Oligonucleotide CDMO Basic Information

Table 62. Catalent, Inc. Peptide and Oligonucleotide CDMO Product Overview

Table 63. Catalent, Inc. Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 64. Catalent, Inc. Business Overview

Table 65. Catalent, Inc. Recent Developments

Table 66. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Basic Information

Table 67. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Overview

Table 68. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 69. Genscript Biotech Corporation Business Overview

Table 70. Genscript Biotech Corporation Recent Developments

Table 71. Polypeptide Group Peptide and Oligonucleotide CDMO Basic Information

Table 72. Polypeptide Group Peptide and Oligonucleotide CDMO Product Overview

Table 73. Polypeptide Group Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 74. Polypeptide Group Business Overview

Table 75. Polypeptide Group Recent Developments

Table 76. Bachem Holding AG Peptide and Oligonucleotide CDMO Basic Information

Table 77. Bachem Holding AG Peptide and Oligonucleotide CDMO Product Overview

Table 78. Bachem Holding AG Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Bachem Holding AG Business Overview

Table 80. Bachem Holding AG Recent Developments

Table 81. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Basic Information

Table 82. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Overview

Table 83. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. Wuxi Apptec Co., Ltd. Business Overview

Table 85. Wuxi Apptec Co., Ltd. Recent Developments

Table 86. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Basic Information

Table 87. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Overview

Table 88. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. Ajinomoto Co., Inc. Business Overview

Table 90. Ajinomoto Co., Inc. Recent Developments

Table 91. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Basic Information

Table 92. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Overview

Table 93. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. Rentschler Biopharma SE Business Overview

Table 95. Rentschler Biopharma SE Recent Developments

Table 96. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Basic Information

Table 97. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Overview

Table 98. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. Corden Pharma GmbH Business Overview

Table 100. Corden Pharma GmbH Recent Developments

Table 101. Senn Chemicals AG Peptide and Oligonucleotide CDMO Basic Information

Table 102. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Overview

Table 103. Senn Chemicals AG Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. Senn Chemicals AG Business Overview

Table 105. Senn Chemicals AG Recent Developments

Table 106. Almac Group Peptide and Oligonucleotide CDMO Basic Information

Table 107. Almac Group Peptide and Oligonucleotide CDMO Product Overview

Table 108. Almac Group Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 109. Almac Group Business Overview

Table 110. Almac Group Recent Developments

Table 111. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Basic Information

Table 112. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Overview

Table 113. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 114. Lonza Custom Manufacturing Business Overview

Table 115. Lonza Custom Manufacturing Recent Developments

Table 116. Creative Peptides Peptide and Oligonucleotide CDMO Basic Information

Table 117. Creative Peptides Peptide and Oligonucleotide CDMO Product Overview

Table 118. Creative Peptides Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 119. Creative Peptides Business Overview

Table 120. Creative Peptides Recent Developments

Table 121. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Basic Information

Table 122. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Overview

Table 123. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 124. Swiss Customized Synthesis Business Overview

Table 125. Swiss Customized Synthesis Recent Developments

Table 126. Syngene Peptide and Oligonucleotide CDMO Basic Information

Table 127. Syngene Peptide and Oligonucleotide CDMO Product Overview

Table 128. Syngene Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 129. Syngene Business Overview

Table 130. Syngene Recent Developments

Table 131. Eurogentec Peptide and Oligonucleotide CDMO Basic Information

Table 132. Eurogentec Peptide and Oligonucleotide CDMO Product Overview

Table 133. Eurogentec Peptide and Oligonucleotide CDMO Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 134. Eurogentec Business Overview

Table 135. Eurogentec Recent Developments

Table 136. Global Peptide and Oligonucleotide CDMO Sales Forecast by Region

(2025-2030) & (K Units)

Table 137. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2025-2030) & (M USD)

Table 138. North America Peptide and Oligonucleotide CDMO Sales Forecast by Country (2025-2030) & (K Units)

Table 139. North America Peptide and Oligonucleotide CDMO Market Size Forecast by Country (2025-2030) & (M USD)

Table 140. Europe Peptide and Oligonucleotide CDMO Sales Forecast by Country (2025-2030) & (K Units)

Table 141. Europe Peptide and Oligonucleotide CDMO Market Size Forecast by Country (2025-2030) & (M USD)

Table 142. Asia Pacific Peptide and Oligonucleotide CDMO Sales Forecast by Region (2025-2030) & (K Units)

Table 143. Asia Pacific Peptide and Oligonucleotide CDMO Market Size Forecast by Region (2025-2030) & (M USD)

Table 144. South America Peptide and Oligonucleotide CDMO Sales Forecast by Country (2025-2030) & (K Units)

Table 145. South America Peptide and Oligonucleotide CDMO Market Size Forecast by Country (2025-2030) & (M USD)

Table 146. Middle East and Africa Peptide and Oligonucleotide CDMO Consumption Forecast by Country (2025-2030) & (Units)

Table 147. Middle East and Africa Peptide and Oligonucleotide CDMO Market Size Forecast by Country (2025-2030) & (M USD)

Table 148. Global Peptide and Oligonucleotide CDMO Sales Forecast by Type (2025-2030) & (K Units)

Table 149. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2025-2030) & (M USD)

Table 150. Global Peptide and Oligonucleotide CDMO Price Forecast by Type (2025-2030) & (USD/Unit)

Table 151. Global Peptide and Oligonucleotide CDMO Sales (K Units) Forecast by Application (2025-2030)

Table 152. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Peptide and Oligonucleotide CDMO
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Peptide and Oligonucleotide CDMO Market Size (M USD), 2019-2030
- Figure 5. Global Peptide and Oligonucleotide CDMO Market Size (M USD) (2019-2030)
- Figure 6. Global Peptide and Oligonucleotide CDMO Sales (K Units) & (2019-2030)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Peptide and Oligonucleotide CDMO Market Size by Country (M USD)
- Figure 11. Peptide and Oligonucleotide CDMO Sales Share by Manufacturers in 2023
- Figure 12. Global Peptide and Oligonucleotide CDMO Revenue Share by Manufacturers in 2023
- Figure 13. Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
- Figure 14. Global Market Peptide and Oligonucleotide CDMO Average Price (USD/Unit) of Key Manufacturers in 2023
- Figure 15. The Global 5 and 10 Largest Players: Market Share by Peptide and Oligonucleotide CDMO Revenue in 2023
- Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 17. Global Peptide and Oligonucleotide CDMO Market Share by Type
- Figure 18. Sales Market Share of Peptide and Oligonucleotide CDMO by Type (2019-2024)
- Figure 19. Sales Market Share of Peptide and Oligonucleotide CDMO by Type in 2023
- Figure 20. Market Size Share of Peptide and Oligonucleotide CDMO by Type (2019-2024)
- Figure 21. Market Size Market Share of Peptide and Oligonucleotide CDMO by Type in 2023
- Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 23. Global Peptide and Oligonucleotide CDMO Market Share by Application
- Figure 24. Global Peptide and Oligonucleotide CDMO Sales Market Share by Application (2019-2024)
- Figure 25. Global Peptide and Oligonucleotide CDMO Sales Market Share by Application in 2023
- Figure 26. Global Peptide and Oligonucleotide CDMO Market Share by Application

(2019-2024)

Figure 27. Global Peptide and Oligonucleotide CDMO Market Share by Application in 2023

Figure 28. Global Peptide and Oligonucleotide CDMO Sales Growth Rate by Application (2019-2024)

Figure 29. Global Peptide and Oligonucleotide CDMO Sales Market Share by Region (2019-2024)

Figure 30. North America Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Peptide and Oligonucleotide CDMO Sales Market Share by Country in 2023

Figure 32. U.S. Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Peptide and Oligonucleotide CDMO Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Peptide and Oligonucleotide CDMO Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Peptide and Oligonucleotide CDMO Sales Market Share by Country in 2023

Figure 37. Germany Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Peptide and Oligonucleotide CDMO Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Peptide and Oligonucleotide CDMO Sales Market Share by Region in 2023

Figure 44. China Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Peptide and Oligonucleotide CDMO Sales and Growth Rate (K Units)

Figure 50. South America Peptide and Oligonucleotide CDMO Sales Market Share by Country in 2023

Figure 51. Brazil Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Peptide and Oligonucleotide CDMO Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Peptide and Oligonucleotide CDMO Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Peptide and Oligonucleotide CDMO Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Peptide and Oligonucleotide CDMO Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Peptide and Oligonucleotide CDMO Sales Market Share Forecast by Type (2025-2030)

Figure 64. Global Peptide and Oligonucleotide CDMO Market Share Forecast by Type (2025-2030)

Figure 65. Global Peptide and Oligonucleotide CDMO Sales Forecast by Application

(2025-2030)

Figure 66. Global Peptide and Oligonucleotide CDMO Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Peptide and Oligonucleotide CDMO Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G508B1BB50E2EN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G508B1BB50E2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

